Dr. Wierda on Immunotherapy Agents for Patients With CLL

William G. Wierda, MD, PhD
Published: Tuesday, May 31, 2016

William G. Wierda, MD, PhD, professor, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses immunotherapy agents being explored in patients with chronic lymphocytic leukemia (CLL).

Chimerica-antigen receptor (CAR) T-cell therapies are being investigated in clinical trials for patients with CLL, Wierda explains. 

Checkpoint inhibitor monoclonal antibodies, which have shown promise and activity in patients with solid tumors, are also being studied in ongoing trials, he adds. Immune manipulation and modulation is a very active area of interest and is a part of oingoing research in CLL.
William G. Wierda, MD, PhD, professor, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses immunotherapy agents being explored in patients with chronic lymphocytic leukemia (CLL).

Chimerica-antigen receptor (CAR) T-cell therapies are being investigated in clinical trials for patients with CLL, Wierda explains. 

Checkpoint inhibitor monoclonal antibodies, which have shown promise and activity in patients with solid tumors, are also being studied in ongoing trials, he adds. Immune manipulation and modulation is a very active area of interest and is a part of oingoing research in CLL.



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: CDK4/6 Inhibitors With the Experts: The Role of Emerging Agents for the Management of Metastatic Breast CancerMay 30, 20182.0
Medical Crossfire®: Clinical Updates on PARP Inhibition and its Evolving Use in the Treatment of CancersMay 30, 20181.5
Publication Bottom Border
Border Publication
x